The disclosure relates to medical devices and in particular to devices and methods that generate therapeutic treatment pulses used in medical devices, such as cardioverters and defibrillators.
A primary task of the heart is to pump oxygenated, nutrient-rich blood throughout the body. Electrical impulses generated by a portion of the heart regulate the pumping cycle. When the electrical impulses follow a regular and consistent pattern, the heart functions normally and the pumping of blood is optimized. When the electrical impulses of the heart are disrupted (i.e., cardiac arrhythmia), this pattern of electrical impulses becomes chaotic or overly rapid, and a sudden cardiac arrest may take place, which inhibits the circulation of blood. As a result, the brain and other critical organs are deprived of nutrients and oxygen. A person experiencing sudden cardiac arrest may suddenly lose consciousness and die shortly thereafter if left untreated.
The most successful therapy for sudden cardiac arrest is prompt and appropriate defibrillation. A defibrillator uses electrical shocks to restore the proper functioning of the heart. A crucial component of the success or failure of defibrillation, however, is time. Ideally, a victim should be defibrillated immediately upon suffering a sudden cardiac arrest, as the victim's chances of survival dwindle rapidly for every minute without treatment.
There are a wide variety of defibrillators. For example, implantable cardioverter-defibrillators (ICD) involve surgically implanting wire coils and a generator device within a person. ICDs are typically for people at high risk for a cardiac arrhythmia. When a cardiac arrhythmia is detected, a current is automatically passed through the heart of the user with little or no intervention by a third party.
Another, more common type of defibrillator is the automated external defibrillator (AED). Rather than being implanted, the AED is an external device used by a third party to resuscitate a person who has suffered from sudden cardiac arrest.
A typical protocol for using the AED 800 is as follows. Initially, the person who has suffered from sudden cardiac arrest is placed on the floor. Clothing is removed to reveal the person's chest 808. The pads 804 are applied to appropriate locations on the chest 808, as illustrated in
Another type of defibrillator is a Wearable Cardioverter Defibrillator (WCD). Rather than a device being implanted into a person at-risk from Sudden Cardiac Arrest, or being used by a bystander once a person has already collapsed from experiencing a Sudden Cardiac Arrest, the WCD is an external device worn by an at-risk person which continuously monitors their heart rhythm to identify the occurrence of an arrhythmia, to correctly identify the type of arrhythmia involved and then to automatically apply the therapeutic action required for the type of arrhythmia identified, whether the therapeutic action is cardioversion or defibrillation. These devices are most frequently used for patients who have been identified as potentially requiring an ICD and to effectively protect them during the two to six month medical evaluation period before a final decision is made and they are officially cleared for, or denied, an ICD.
The current varieties of defibrillators available on the market today, whether Implantable Cardioverter Defibrillators (ICDs) or Automatic External Defibrillators (AEDs) or any other variety such as Wearable Cardioverter Defibrillators (WCDs), predominantly utilize either a monophasic waveform or a biphasic waveform for the therapeutic defibrillation high-energy pulse. Each manufacturer of defibrillators, for commercial reasons, has their own unique and slightly different take on waveform design for their devices' pulses. Multiple clinical studies over the last couple of decades have indicated that use of a biphasic waveform has greater therapeutic value than a monophasic waveform does to a patient requiring defibrillation therapy and that biphasic waveforms are efficacious at lower levels of energy delivery than monophasic waveforms.
All of the current products that use a biphasic waveform pulse have a single high-energy reservoir, which, while simple and convenient, results in severe limitation on the range of viable pulse shapes that can be delivered. Specifically, the second or Negative phase of the Biphasic waveform is currently characterized by a lower amplitude starting point than the first or Positive phase of the Biphasic waveform, as shown in
The disclosure is particularly applicable to a multiphasic pulse system for an external defibrillator and it is in this context that the disclosure will be described. It will be appreciated, however, that the multiphasic pulse system has greater utility since it may be used to generate one or more pulses for other systems. For example, the pulse system may be used to generate therapeutic treatment pulses for other types of defibrillators, cardioverters or other systems. For example, the pulse system may be used to generate therapeutic treatment pulses and then provide the pulses to a patient using paddles or pads. When used for defibrillation, the pulse system may generates the pulses and deliver them to a patient through two defibrillation pads or paddles.
The multiphasic pulse system overcomes the limitation on the amplitude of follow on phases of the pulse waveform by using two or more high-energy reservoirs and/or sources, such as the four shown in
Each subsystem 12, 14 of each side, as shown in
The control logic and heart rhythm sense component 20 is well known in the art and the component analyzes the ECG signals from the patient for treatable arrhythmias and then chooses to shock the patient when a treatable arrhythmia is detected, along with guiding the operator through both visual and audible means through this process when the device is of the external automated variety. The control logic and heart rhythm sense component 20 also may control and shape the therapeutic pulse as it is delivered from the energy reservoir and ensures that it is as optimal as possible for the individual patient. In the implementations shown in
In one implementation, each control logic in each subsystem may have a circuit that can be used to adjust the shape of each portion of the therapeutic pulse. The circuit, may be for example, an array of resistors of various strengths and switches so that one or more of the resistor may be selected (as an array of selectable resistors) that can optimize and alter an RC constant of a subsystem's pulse phase generating circuitry in order to dynamically shape one or more pulse phases.
In some embodiments of the system, the system may provide for the recharging of individual energy reservoirs by the energy sources during times (including inter-pulse times) that an individual energy reservoir is not selected for discharge as shown in
In one implementation, the system 10 may consist of two or more high-energy therapeutic pulse delivery sub-systems 12, 14 as shown in
The system 10 may either be pre-programmed to use a specific single multiphasic pulse shape, according to which one is shown to be most efficacious in clinical lab testing/trials, or else it may select the best one for a given purpose from a lookup table where they are listed according to their suitability for optimally resolving different types of arrhythmia that are being screened for and identified or for the different treatments as described above. Regardless, the system and method allows the use and application of a much wider range of pulse shapes than has been previously possible and this will allow the devices which use this invention to keep up with clinical developments as waveforms continue to be improved.
As shown in
Each portion 402, 404 of the H-bridge has its own energy source, 1600 VDC in the example in
In the system, a therapeutic pulse may comprise one or more positive pulses and one or more negative pulses. As shown in
While the foregoing has been with reference to a particular embodiment of the invention, it will be appreciated by those skilled in the art that changes in this embodiment may be made without departing from the principles and spirit of the disclosure, the scope of which is defined by the appended claims.
This application claims priority to under 35 USC 120 and a continuation of U.S. patent application Ser. No. 14/303,541, filed Jun. 12, 2014 and titled “Dynamically Adjustable Multiphasic Defibrillator Pulse System And Method” (issued as U.S. Pat. No. 9,616,243) which in turn claims priority under 35 USC 120 and claims the benefit under 35 USC 119(e) to U.S. Provisional Patent Application Ser. No. 61/835,443 filed Jun. 14, 2013 and titled “Dynamically Adjustable Multiphasic Defibrillator Pulse System and Method”, the entirety of all of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4441498 | Nordling | Apr 1984 | A |
5199429 | Kroll et al. | Apr 1993 | A |
5240995 | Gyory | Aug 1993 | A |
5290585 | Elton | Mar 1994 | A |
5338490 | Dietz | Aug 1994 | A |
5362420 | Itoh | Nov 1994 | A |
5402884 | Gilman et al. | Apr 1995 | A |
5489624 | Kantner | Feb 1996 | A |
5536768 | Kantner | Jul 1996 | A |
5573668 | Grosh | Nov 1996 | A |
5643252 | Waner et al. | Jul 1997 | A |
5658316 | Lamond et al. | Aug 1997 | A |
5660178 | Kantner | Aug 1997 | A |
5733310 | Lopin et al. | Mar 1998 | A |
5800685 | Perrault | Sep 1998 | A |
5871505 | Adams | Feb 1999 | A |
5987354 | Cooper | Nov 1999 | A |
6004312 | Finneran et al. | Dec 1999 | A |
6006131 | Cooper et al. | Dec 1999 | A |
6056738 | Marchitto et al. | May 2000 | A |
6141584 | Rockwell et al. | Oct 2000 | A |
6197324 | Crittenden | Mar 2001 | B1 |
6251100 | Flock et al. | Jun 2001 | B1 |
6256533 | Yuzhakov et al. | Jul 2001 | B1 |
6266563 | Kenknight et al. | Jul 2001 | B1 |
6315722 | Yaegashi | Nov 2001 | B1 |
6329488 | Terry | Dec 2001 | B1 |
6379324 | Gartstein et al. | Apr 2002 | B1 |
6477413 | Sullivan | Nov 2002 | B1 |
6576712 | Feldstein | Jun 2003 | B2 |
6596401 | Terry | Jul 2003 | B1 |
6597948 | Rockwell et al. | Jul 2003 | B1 |
6611707 | Prausnitz | Aug 2003 | B1 |
6690959 | Thompson | Feb 2004 | B2 |
6714817 | Daynes et al. | Mar 2004 | B2 |
6797276 | Glenn | Sep 2004 | B1 |
6803420 | Cleary | Oct 2004 | B2 |
6908453 | Fleming | Jun 2005 | B2 |
6908681 | Terry | Jun 2005 | B2 |
6931277 | Yuzhakov | Aug 2005 | B1 |
7072712 | Kroll et al. | Jul 2006 | B2 |
7108681 | Gartstein | Sep 2006 | B2 |
7215991 | Besson et al. | May 2007 | B2 |
7226439 | Pransnitz | Jun 2007 | B2 |
7463917 | Martinez | Dec 2008 | B2 |
7645263 | Angel et al. | Jan 2010 | B2 |
7797044 | Covey et al. | Sep 2010 | B2 |
8024037 | Kumar et al. | Sep 2011 | B2 |
8527044 | Edwards et al. | Sep 2013 | B2 |
8558499 | Ozaki et al. | Oct 2013 | B2 |
8615295 | Savage et al. | Dec 2013 | B2 |
8781576 | Savage et al. | Jul 2014 | B2 |
9089718 | Owen et al. | Jul 2015 | B2 |
9101778 | Savage et al. | Aug 2015 | B2 |
9616243 | Raymond | Apr 2017 | B2 |
9656094 | Raymond | May 2017 | B2 |
20010031992 | Fishler et al. | Oct 2001 | A1 |
20010051819 | Fishler et al. | Dec 2001 | A1 |
20020016562 | Cormier et al. | Feb 2002 | A1 |
20020045907 | Sherman et al. | Apr 2002 | A1 |
20020082644 | Picardo et al. | Jun 2002 | A1 |
20030017743 | Picardo et al. | Jan 2003 | A1 |
20030055460 | Owen et al. | Mar 2003 | A1 |
20030088279 | Rissmann et al. | May 2003 | A1 |
20030125771 | Garrett | Jul 2003 | A1 |
20030167075 | Fincke | Sep 2003 | A1 |
20030197487 | Tamura et al. | Oct 2003 | A1 |
20040105834 | Singh | Jun 2004 | A1 |
20040143297 | Ramsey, III | Jul 2004 | A1 |
20040166147 | Lundy | Aug 2004 | A1 |
20040247655 | Asmus | Dec 2004 | A1 |
20050055460 | Johnson et al. | Mar 2005 | A1 |
20050107713 | Van Herk | May 2005 | A1 |
20050123565 | Subramony | Jun 2005 | A1 |
20060136000 | Bowers | Jun 2006 | A1 |
20060142806 | Katzman et al. | Jun 2006 | A1 |
20060173493 | Armstrong et al. | Aug 2006 | A1 |
20060206152 | Covey et al. | Sep 2006 | A1 |
20070016268 | Carter et al. | Jan 2007 | A1 |
20070078376 | Smith | Apr 2007 | A1 |
20070135729 | Ollmar et al. | Jun 2007 | A1 |
20070143297 | Recio et al. | Jun 2007 | A1 |
20070150008 | Jones et al. | Jun 2007 | A1 |
20070191901 | Schecter | Aug 2007 | A1 |
20080082153 | Gadsby et al. | Apr 2008 | A1 |
20080097546 | Powers et al. | Apr 2008 | A1 |
20080154110 | Burnes et al. | Jun 2008 | A1 |
20080154178 | Carter et al. | Jun 2008 | A1 |
20080177342 | Snyder | Jul 2008 | A1 |
20080312579 | Chang et al. | Dec 2008 | A1 |
20080312709 | Volpe et al. | Dec 2008 | A1 |
20090005827 | Weintraub et al. | Jan 2009 | A1 |
20090076366 | Palti | Mar 2009 | A1 |
20090210022 | Powers | Aug 2009 | A1 |
20090318988 | Powers | Dec 2009 | A1 |
20090326400 | Huldt | Dec 2009 | A1 |
20100063559 | McIntyre et al. | Mar 2010 | A1 |
20100160712 | Burnett et al. | Jun 2010 | A1 |
20100181629 | Hoefler et al. | Jul 2010 | A1 |
20100191141 | Aberg | Jul 2010 | A1 |
20100241181 | Savage et al. | Sep 2010 | A1 |
20100249860 | Shuros et al. | Sep 2010 | A1 |
20110028859 | Chian | Feb 2011 | A1 |
20110071611 | Khuon et al. | Mar 2011 | A1 |
20110208029 | Joucla et al. | Aug 2011 | A1 |
20110237922 | Parker, III et al. | Sep 2011 | A1 |
20110288604 | Kaib et al. | Nov 2011 | A1 |
20110301683 | Axelgaard | Dec 2011 | A1 |
20120101396 | Solosko et al. | Apr 2012 | A1 |
20120112903 | Kalb et al. | May 2012 | A1 |
20120136233 | Yamashita | May 2012 | A1 |
20120158075 | Kaib et al. | Jun 2012 | A1 |
20120158078 | Moulder et al. | Jun 2012 | A1 |
20120203297 | Efimov et al. | Aug 2012 | A1 |
20120259382 | Trier | Oct 2012 | A1 |
20130018251 | Caprio et al. | Jan 2013 | A1 |
20130144365 | Kipke et al. | Jun 2013 | A1 |
20140005736 | Geheb | Jan 2014 | A1 |
20140039593 | Savage et al. | Feb 2014 | A1 |
20140039594 | Savage et al. | Feb 2014 | A1 |
20140221766 | Kinast | Aug 2014 | A1 |
20140276183 | Badower | Sep 2014 | A1 |
20140277226 | Poore et al. | Sep 2014 | A1 |
20140317914 | Shaker | Oct 2014 | A1 |
20140371566 | Raymond et al. | Dec 2014 | A1 |
20140371567 | Raymond et al. | Dec 2014 | A1 |
20140371805 | Raymond et al. | Dec 2014 | A1 |
20140371806 | Raymond et al. | Dec 2014 | A1 |
20150297104 | Chen et al. | Oct 2015 | A1 |
20150327781 | Hernandez-Silveira | Nov 2015 | A1 |
20160206893 | Raymond et al. | Jul 2016 | A1 |
20160213933 | Raymond et al. | Jul 2016 | A1 |
20160213938 | Raymond et al. | Jul 2016 | A1 |
20160296177 | Gray et al. | Oct 2016 | A1 |
20160361533 | Savage et al. | Dec 2016 | A1 |
20160361555 | Savage et al. | Dec 2016 | A1 |
Number | Date | Country |
---|---|---|
10 2006 02586 | Dec 2007 | DE |
1 530 983 | May 2005 | EP |
1 834 622 | Sep 2007 | EP |
2000-093526 | Jan 1917 | JP |
2011-512227 | Sep 1917 | JP |
2005-144164 | Jun 2005 | JP |
2007-530124 | Nov 2007 | JP |
2008-302254 | Dec 2008 | JP |
2010-511438 | Apr 2010 | JP |
2010-529897 | Sep 2010 | JP |
2012-135457 | Jul 2012 | JP |
2012-529954 | Nov 2012 | JP |
WO 03020362 | Mar 2003 | WO |
WO 2010146492 | Dec 2010 | WO |
WO2010151875 | Dec 2010 | WO |
Entry |
---|
Claims of U.S. Appl. No. 14/661,949, filed Dec. 15, 2016 (now U.S. Pat. No. 9,656,094). |
Yamanouchi, Yoshio, et al. “Optimal Small-Capacitor Biphasic Waveform for External Defibrillation: Influence of Phase-1 Tilt and Phase-2 Voltage.” Jul. 30, 1998. Journal of the American Heart Association, vol. 98. pp. 2487-2493. |
CN 201080021650.4, First Office Action dated Jul. 24, 2013 (English and Chinese) (19 pgs.). |
CN 201080021650.4, Second Office Action dated Jan. 16, 2014 (English and Chinese) (16 pgs.). |
CN 201080021650.4, Third Office Action dated Jun. 17, 2014 (English and Chinese) (18 pgs.). |
JP 2012-500855, Notification of Reason for Rejection dated Feb. 17, 2014 (English and Japanese) (3 pgs.). |
JP 2014-545921, Notification of Reason for Rejection dated Jun. 1, 2015 (English and Japanese) (7 pgs.). |
EP 2408521—Extended European Search Report dated Jul. 10, 2012 (8 pgs.). |
PCT/EP2007/009879—PCT International Preliminary Report on Patentability dated May 19, 2009 (7 pgs.). |
PCT/EP2007/009879—PCT International Search Report dated Apr. 29, 2008 (3 pgs.). |
PCT/EP2007/009879—PCT International Written Opinion dated Apr. 29, 2008 (6 pgs.). |
PCT/US2010/027346—PCT International Preliminary Report on Patentability, dated Sep. 20, 2011 (12 pgs.). |
PCT/US2010/027346—PCT International Search Report dated Oct. 14, 2010 (4 pgs.). |
PCT/US2010/027346—PCT Written Opinion of the International Searching Authority dated Oct. 14, 2010 (7 pgs.). |
PCT/US2012/065712—PCT International Search Report dated Mar. 29, 2013 (2 pgs.). |
PCT/US2012/065712—PCT Written Opinion dated Mar. 29, 2013 (5 pgs.). |
PCT/US2012/65712—PCT International Preliminary Report on Patentability dated Jun. 10, 2014 (6 pgs.). |
PCT/US2014/42355—PCT International Search Report dated Nov. 3, 2010 (2 pgs.). |
PCT/US2014/42355—PCT Written Opinion dated Nov. 3, 2014 (6 pgs.). |
PCT/US2014/42356—PCT International Search Report dated Nov. 3, 2010 (2 pgs.). |
PCT/US2014/42356—PCT Written Opinion dated Nov. 3, 2014 (6 pgs.). |
PCT/US2014/42360—PCT International Search Report dated Nov. 4, 2010 (2 pgs.). |
PCT/US2014/42360—PCT Written Opinion dated Nov. 4, 2014 (4 pgs.). |
PCT/US2014/42409—PCT International Search Report dated Nov. 4, 2010 (2 pgs.). |
PCT/US2014/42409—PCT Written Opinion dated Nov. 4, 2014 (4 pgs.). |
Changes in the passive electrical properties of human stratum corneum due electroporation, dated Dec. 7, 1994. By U. Pliquett, R. Langer, and J. C. Weaver (11 pgs.). |
Electrical properties of the epidermal stratum corneum, dated Aug. 12, 1974. By T. Yamamoto and Y. Yamamoto (8 pgs.). |
Insertion of microneedles into skin: measurement and prediction of insertion force and needle facture force, dated Dec. 10, 2003. By S. P. Davis, B. J. Landis, Z. H. Adams, M. G. Allen, and M. R. Prausnitz (9 pgs.). |
Lack of Pain Associated with Microfabricated Microneedles, dated Oct. 10, 2000. By S. Kaushik, A. H. Hord, D. D. Denson, D. V. McAlliser, S. Smitra, M. G. Allen, and M. R. Prausnitz (3 pgs.). |
Microneedle Insertion Force Reduction Using Vibratory Actuation, dated 2004. By M. Yang and J. D. Zahn (6 pgs.). |
Non-invasive bioimpedance of intact skin: mathematical modeling and experiments, dated May 2, 2010. By U. Birgersson, E. Birgersson, P. Aberg, I. Nicander, and S. Ollmar (19 pgs.). |
Optimal Small-Capacitor Biphasic Waveform for External Defibrillation; Influence of Phase-1 Tilt and Phase-2 Voltage, By Yoshio Yamanouchi, et al. , Journal of the American Heart Association, Dec. 1, 1998, vol. 98, pp. 2487-2493 (8 pgs.). |
Polymer Microneedles for Controlled-Release Drug Delivery, dated Dec. 2, 2005. By J-H. Park, M. G. Allen, and M. R. Prausnitz (12 pgs.). |
Two Dimensional Metallic Microelectrode Arrays for Extracellular Stimulation and Recording of Neurons, dated 1993. By A. B. Frazier, D. P. O'Brien, and M. G. Allen (6 pgs.). |
Utilizing Characteristic Electrical Properties of the Epidermal Skin Layers to Detect Fake Fingers in Biometric Fingerprint Systems-A Pilot Study, dated Dec. 1, 2004. By O. G. Martinsen, S. Clausen, J. B. Nysaether, and S. Grimnes (4 pgs.). |
Number | Date | Country | |
---|---|---|---|
20170216612 A1 | Aug 2017 | US |
Number | Date | Country | |
---|---|---|---|
61835443 | Jun 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14303541 | Jun 2014 | US |
Child | 15484055 | US |